8-K: Medicus Pharma Ltd. Secures $7 Million in Public Offering to Advance Basal Cell Carcinoma Clinical Trials

Medicus Pharma Ltd. successfully closed a $7.0 million public offering, with proceeds earmarked primarily for advancing its basal cell carcinoma clinical trials and other strategic initiatives.

Summary

• Medicus Pharma Ltd. completed a public offering of 2,260,000 units at a price of $3.10 per unit, generating aggregate gross proceeds of $7,006,000.
• Each unit consists of one common share and one warrant to purchase one common share, with warrants exercisable at $3.10 per share and expiring five years from the date of issuance.
• The company intends to use the net proceeds from the offering to fund its Phase 2 proof of concept clinical trial for treatment of basal cell carcinoma using its doxorubicin tip loaded dissolvable microarray needle skinpatch.
• Proceeds may also be used to expand the exploratory Phase 2 clinical trial to a pivotal trial, expand trials to cover other non-melanoma skin diseases, and for general corporate purposes and working capital.
• Medicus also received an additional $1,125,000 in net proceeds from the purchase of a $1,250,000 debenture by YA II PN, Ltd. (Yorkville) on June 2, 2025, following an initial $1,125,000 from a $1,250,000 debenture on May 2, 2025, totaling $2,250,000 in net proceeds from debentures.
• The company previously announced entering into a binding letter of intent in April 2025 to acquire Antev Ltd., a UK-based late clinical stage biotech company developing Teverelix, a next generation GnRH antagonist.

Sentiment

Score: 7

Explanation: The successful completion of a public offering and additional debenture funding provides Medicus Pharma with necessary capital to advance its clinical pipeline, particularly for basal cell carcinoma and potentially through the Antev acquisition. This financial strengthening and clear strategic direction are positive, despite the dilution from the offering and the 'best-efforts' nature.

Positives

• Successful completion of a $7.0 million public offering, strengthening the company's financial position for clinical development.
• Secured additional debenture funding of $1.125 million, totaling $2.25 million in net proceeds from Yorkville, providing further capital.
• Proceeds are specifically allocated to advance key clinical trials for basal cell carcinoma, indicating focused progress in its core therapeutic area.
• The potential acquisition of Antev Ltd. could diversify Medicus Pharma's pipeline with a late-stage GnRH antagonist (Teverelix) for prostate cancer and acute urinary retention.
• Positive Phase 1 safety and tolerability results for SkinJect's D-MNA, with six participants experiencing complete response on histological examination of the resected lesion.
• Ongoing multicenter clinical studies (SKNJCT-003 in US/Europe and SKNJCT-004 in UAE) for SkinJect's basal cell carcinoma treatment demonstrate active development.

Negatives

• The offering was conducted on a 'best-efforts' basis, which carries a higher risk of not raising the full target amount compared to a firm commitment underwriting.
• Placement agent fees of 7.5% of gross proceeds, along with other expenses, reduce the net capital available to the company from the offering.
• The issuance of 2,260,000 new common shares and 2,260,000 warrants will result in immediate and potential future dilution for existing shareholders.
• The warrants issued in the offering will not trade on any securities exchange, limiting liquidity for warrant holders.
• The acquisition of Antev Ltd. is subject to significant conditions, including satisfactory due diligence and negotiation of definitive agreements, with no assurance of completion.

Risks

• Forward-looking statements regarding the use of net proceeds and future developments are inherently subject to factors, risks, uncertainties, and assumptions, and actual results may vary materially.
• There is no assurance that the potential acquisition of Antev Ltd. will be consummated on the terms or timeframe currently contemplated, or at all, as it is subject to due diligence, definitive agreements, and various approvals.
• The company disclaims any intention or obligation to update or revise any forward-looking statements after they are made, except as required by law or regulation, which may limit timely disclosure of changes.

Future Outlook

The company expects to use the net proceeds from the offering to fund its Phase 2 proof of concept clinical trial for basal cell carcinoma, potentially expanding it to a pivotal trial or covering other non-melanoma skin diseases, with any remaining proceeds for general corporate purposes and working capital. The potential acquisition of Antev Ltd. aims to expand its pipeline with Teverelix for prostate cancer patients.

Management Comments

• "The Company intends to use any net proceeds from the offering to fund its Phase 2 proof of concept clinical trial for treatment of basal cell carcinoma using its doxorubicin tip loaded dissolvable microarray needle skinpatch."
• "The Company may also use the net proceeds of the offering to expand its exploratory phase 2 clinical trial to a pivotal trial and/or to expand its trials to cover other non-melanoma skin diseases."
• "The company will use any remaining net proceeds for general corporate purposes and working capital."
• "Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets."
• "SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells."
• "The Company has completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion."
• "The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in United States and Europe."
• "The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in UAE."
• "In April 2025, the company also announced entering into a binding letter of intent to acquire Antev Ltd. ('Antev'), a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged prostate."

Industry Context

This offering positions Medicus Pharma to further its clinical development in dermatology, specifically for non-melanoma skin cancers, a significant market. The potential acquisition of Antev Ltd. signals a strategic diversification into oncology/urology with a late-stage asset, which could broaden its therapeutic focus and market reach, aligning with a trend of biotech companies seeking to expand their pipelines through M&A. The 'best-efforts' nature of the offering is common for smaller biotech firms raising capital.

Comparison to Industry Standards

• The $7.0 million capital raise, while substantial for Medicus Pharma, is relatively modest compared to the typical capital requirements for late-stage clinical development and commercialization in the broader pharmaceutical industry, where pivotal trials can cost hundreds of millions.
• The 7.5% placement agent fee is within the typical range for 'best-efforts' offerings by smaller capitalization companies, which often face higher underwriting costs than larger, more established firms.
• The Phase 1 results for SkinJect's D-MNA, showing complete histological response in 6 participants, are promising for a novel drug delivery system in basal cell carcinoma, a common cancer. However, these are early-stage results and larger, pivotal trials (SKNJCT-003, SKNJCT-004) are crucial for demonstrating broader efficacy and safety, similar to other dermatology drug developers like Leo Pharma or Sun Pharmaceutical Industries.
• The acquisition of Antev Ltd. and its Teverelix asset, a GnRH antagonist, could place Medicus in competition with established players in prostate cancer treatment, such as AstraZeneca (with Faslodex) or AbbVie (with Orgovyx), though Teverelix's 'next generation' and 'first in market' claims suggest a differentiated profile.

Corporate Governance

Related Party Transactions

• Securities Purchase Agreement with YA II PN, Ltd. ('Yorkville') for debentures totaling $2,500,000 principal amount.
• Support agreement, dated September 28, 2023, between the Company and Velocity Fund Partners, LP.

Stakeholder Impact

• Shareholders: Experience dilution from the issuance of 2,260,000 new common shares and potential future dilution from the exercise of 2,260,000 warrants. However, the capital raise provides funding for clinical development, which could enhance long-term value.
• Investors (New): Acquired units consisting of common shares and warrants at $3.10 per unit, gaining exposure to the company's clinical pipeline.
• Employees: Continued funding for clinical trials supports ongoing R&D activities and job security within the company's development teams.
• Customers/Patients: The funding directly supports the advancement of clinical trials for basal cell carcinoma and potentially other non-melanoma skin diseases, aiming to bring new therapeutic options to market.
• Creditors: The additional debenture funding increases the company's debt, but the capital raise also improves liquidity and financial stability for operations.

Next Steps

• Fund Phase 2 proof of concept clinical trial for basal cell carcinoma using doxorubicin tip loaded dissolvable microarray needle skinpatch.
• Potentially expand exploratory Phase 2 clinical trial to a pivotal trial.
• Potentially expand trials to cover other non-melanoma skin diseases.
• Continue negotiations and due diligence for the acquisition of Antev Ltd.
• Obtain applicable corporate, regulatory, and third-party approvals for the Antev transaction.
• Fulfill customary closing conditions for the Antev transaction.
• Maintain listing of shares on The Nasdaq Capital Market for at least one year.
• Maintain effectiveness of the Registration Statement and a current Prospectus for as long as the warrants remain outstanding.

Key Dates

Recommendation

Keywords

Medicus Pharma, MDCX, Public Offering, Capital Raise, Common Shares, Warrants, Clinical Trials, Basal Cell Carcinoma, SkinJect, Doxorubicin, Microneedle Patch, Non-Melanoma Skin Diseases, Antev Ltd., Teverelix, GnRH Antagonist, Prostate Cancer, Biotech, Life Sciences, NASDAQ